Management of Allergic Urticaria with Loratadine and Alternative Therapies

Introduction to Loratadine Dosing

The American Academy of Allergy, Asthma, and Immunology recommends starting with loratadine 10 mg once daily, and if inadequate control occurs after 2-4 weeks, increase the dose up to 4-fold (40 mg daily) before switching to other treatments 1
Current guidelines explicitly support increasing antihistamine doses beyond standard recommendations when potential benefits outweigh risks, which is now common clinical practice 2
Higher doses of loratadine demonstrate enhanced "antiallergic" effects on mast-cell mediator release 1
Allow 2-4 weeks at each dose level before escalating further to properly assess response 1

The British Association of Dermatologists recommends cooling antipruritic lotions such as 1% menthol in aqueous cream as soothing topical alternatives to calamine 2
1% menthol in aqueous cream provides cooling relief and is explicitly recommended in guidelines 2
High-potency topical corticosteroids (clobetasol propionate, halobetasol propionate, betamethasone dipropionate) are recommended for body areas 3
Low-potency topical corticosteroids (hydrocortisone 2.5%, desonide, aclometasone) are recommended for facial areas 3
Emollients with cream or ointment-based, fragrance-free products help maintain skin barrier 3

Patients should be offered a choice of at least two different nonsedating antihistamines because individual responses and tolerance vary significantly 2, 1
Cetirizine 10 mg daily reaches maximum concentration fastest, advantageous for rapid symptom control, but may cause sedation at 13.7% vs 6.3% placebo 4, 1
Fexofenadine is completely non-sedating at all doses 1
Desloratadine has the longest elimination half-life at 27 hours, and is completely non-sedating 2, 1

Adding H2 antihistamines may provide better urticaria control than H1 antihistamines alone 1
Adding montelukast 10 mg to antihistamine therapy equals the efficacy of doubled antihistamine doses but with significantly less sedation 1
Omalizumab 300 mg every 4 weeks is recommended as second-line therapy if inadequate control persists despite 4-fold antihistamine dosing 1

Don't combine first-generation antihistamines at bedtime with second-generation agents during the day, as first-generation agents cause prolonged daytime drowsiness despite nighttime dosing 1
Don't assume all second-generation antihistamines are equally non-sedating: cetirizine may cause sedation especially at higher doses, while loratadine, fexofenadine, and desloratadine do not 4, 1
Avoid NSAIDs and aspirin in patients with urticaria as they can worsen symptoms through cyclooxygenase inhibition 2
Minimize nonspecific aggravating factors such as overheating, stress, and alcohol 2

Assess disease control using the Urticaria Control Test (UCT): patients with UCT score ≤16 require dose escalation 1
Once complete disease control is achieved for 3 consecutive months, consider gradual dose reduction by no more than 1 tablet per month 1
If breakthrough symptoms occur, return to the last dose that provided complete control 1